This study introduces new theranostic tools that combine the UniCAR peptide epitope E5B9 with the metabolically stable GRPR-targeting peptide bombesin antagonist BBN2 in monomeric and dimeric forms for imaging and treatment of prostate cancers. Here, GRPR is linked to prostate cancer.